Developer docs
API playgroundTry for free, no card

Search company profiles

BeiGene

Full company profile

uuid0000941

Namestring
BeiGene
Legal namestring
BeOne Medicines I GmbH
Websiteurl
beigene.com
Company typeenum
Public
Founded yearint
2010
Descriptiontext

BeOne Medicines I GmbH, operating as BeOne Medicines and formerly known as BeiGene, is a global oncology company founded in 2010 and headquartered in Basel, Switzerland (with major operations in Beijing and San Mateo). The company is dual-listed on NASDAQ (ticker ONC), HKEX, and the Shanghai Stock Exchange and markets three approved cancer medicines: BRUKINSA (zanubrutinib), the leading global BTK inhibitor approved in more than 80 markets and generating $3.9 billion in FY2025 sales at 49% year-over-year growth; TEVIMBRA (tislelizumab), a PD-1 inhibitor approved in multiple solid tumor indications; and BEQALZI (sonrotoclax), the first and only FDA-approved BCL2 inhibitor for B-cell malignancies, approved in May 2026.

The company's pipeline spans hematology and solid tumors and includes BTK degraders (BGB-16673/tacabrutideg), a CDK4 inhibitor entering Phase 3 for first-line metastatic breast cancer, the anti-TIGIT antibody ociperlimab, the HPK1 inhibitor BGB-26808, the PRMT5 inhibitor BGB-58067, and the GPC3×4-1BB bispecific BGB-B2033. Underlying these programs are two proprietary technology platforms: CDAC (Conditionally Active Biodegradable Antibody Conjugates), a protein degradation modality, and an enhanced Antibody Drug Conjugate (ADC) platform. Clinical differentiation is anchored by long-duration efficacy data, including 71.8% progression-free survival at 78-month follow-up in CLL/SLL (SEQUOIA trial) and an 85.1% overall response rate for the BTK degrader in heavily pretreated relapsed/refractory CLL.

BeOne Medicines operates a hybrid commercial model: direct sales infrastructure across more than 80 markets including the US, EU, and China, supplemented by licensing partnerships such as the Glenmark deal for emerging markets and the Jazz Pharmaceuticals collaboration on zanidatamab (Ziihera). FY2025 product revenue reached $5.3 billion (40% year-over-year growth) at 88% gross margin, generating the company's first full-year GAAP net profit of $287 million and more than $940 million in free cash flow. Amgen holds an approximately 20.5% equity stake acquired in 2020.

Short descriptiontext

BeOne Medicines (formerly BeiGene) is a global oncology company developing and commercializing BRUKINSA, TEVIMBRA, and BEQALZI across 80+ markets, with proprietary protein degradation (CDAC) and ADC platforms and a deep hematology and solid tumor pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology pharmaceuticals, cancer immunotherapy, BTK inhibitors, PD-1 inhibitors, hematology treatments
Industry3 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Pharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Product Revenue - BRUKINSA
TypeOne Time License
Description

BRUKINSA (zanubrutinib) is the company's flagship BTK inhibitor generating $3.9 billion in global sales in FY2025, representing 49% year-over-year growth. The drug is approved in 80 markets and maintains position as the leading BTK inhibitor globally. BRUKINSA generated $1.1 billion in Q4 2025 and is on track to generate approximately $5 billion in revenue in 2026.

businesswire.com
2Product Revenue - Tevimbra
TypeOne Time License
Description

Tevimbra (tislelizumab) is the company's PD-1 inhibitor generating $206 million in Q1 2026 revenue, 7% above analyst estimates. The drug is approved in multiple indications and received priority review from US FDA for first-line HER2+ gastroesophageal adenocarcinoma.

in.investing.com
3Product Revenue - BEQALZI (sonrotoclax)
TypeOne Time License
Description

BEQALZI (sonrotoclax) received FDA approval in May 2026 as the first and only BCL2 inhibitor for certain B-cell malignancies, representing a new revenue stream for the company. The drug has also received Breakthrough Therapy Designation for relapsed or refractory mantle cell lymphoma.

simplywall.st
4Partnership Revenue - Zanidatamab/Ziihera
TypeLicensing Royalties
Description

BeOne Medicines partnered with Zymeworks on zanidatamab (Ziihera), which received FDA approval for biliary tract cancer and is being developed for HER2-positive gastroesophageal adenocarcinoma. The partnership includes milestone payments and royalty streams, with Jazz Pharmaceuticals collaborating on commercialization.

benzinga.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BeOne Medicines is a global oncology company that discovers, develops, manufactures, and commercializes proprietary cancer therapeutics. Its portfolio spans approved drugs (BRUKINSA BTK inhibitor, TEVIMBRA PD-1 inhibitor, BEQALZI BCL2 inhibitor) for hematologic malignancies and solid tumors, plus a deep pipeline of investigational BTK degraders, bispecific antibodies, CDK4/PRMT5/HPK1 inhibitors and TIGIT antibodies. The company operates direct commercial infrastructure across 80+ markets and licenses products in emerging geographies to broaden patient access.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 74% progression-free survival at 6 years in treatment-naïve CLL patients with BRUKINSA
+5 more records
Product overview1 text field

BeOne Medicines (BeiGene) is a global oncology company developing a broad portfolio of cancer medicines. The company's approved products include BRUKINSA (zanubrutinib), a leading BTK inhibitor approved in over 80 markets for B-cell malignancies; TEVIMBRA (tislelizumab), a PD-1 inhibitor for various solid tumors; and BEQALZI (sonrotoclax), a BCL2 inhibitor approved in May 2026. The pipeline includes investigational BTK degraders (BGB-16673, tacabrutideg), a PRMT5 inhibitor (BGB-58067), a bispecific antibody (BGB-B2033), a TIGIT inhibitor (ociperlimab), an HPK1 inhibitor (BGB-26808), and a CDK4 inhibitor in Phase 3 development. The company also develops proprietary technology platforms including CDAC (protein degradation) and ADC (antibody drug conjugates). Research focuses on hematology (blood cancers) and solid tumors (breast, gynecologic, gastrointestinal, lung, liver cancers).

Product and service4 records
1BRUKINSA (zanubrutinib)
CategoryOncology Pharmaceuticals — BTK Inhibitor
Description

Bruton's tyrosine kinase (BTK) inhibitor approved for the treatment of B-cell malignancies including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Waldenström's macroglobulinemia, and marginal zone lymphoma. BRUKINSA is the leading BTK inhibitor globally, approved in 80+ markets, and generated $3.9B in FY2025 sales with 49% YoY growth.

2TEVIMBRA (tislelizumab)
CategoryOncology Pharmaceuticals — PD-1 Inhibitor
Description

Anti-PD-1 monoclonal antibody approved in multiple indications for the treatment of various solid tumors, including lung cancer and HER2-positive gastroesophageal adenocarcinoma. TEVIMBRA generated $206 million in Q1 2026 revenue and has received U.S. FDA Priority Review for first-line HER2+ GEA.

3BEQALZI (sonrotoclax)
CategoryOncology Pharmaceuticals — BCL2 Inhibitor
Description

Next-generation BCL2 inhibitor approved by the U.S. FDA in May 2026 as the first and only BCL2 inhibitor for certain B-cell malignancies. Demonstrated 100% ORR with 59.5% complete responses in treatment-naive CLL patients and has also received Breakthrough Therapy Designation for relapsed or refractory mantle cell lymphoma.

4Ziihera (zanidatamab)
CategoryOncology Pharmaceuticals — HER2 Bispecific Antibody
Description

HER2-targeted bispecific antibody partnered with Zymeworks and co-commercialized with Jazz Pharmaceuticals for HER2-positive cancers. Approved for biliary tract cancer with positive Phase 3 data in gastroesophageal adenocarcinoma; eligible for up to $1.5 billion in potential milestone payments.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

Expanded multi-year partnership announced June 2026 with BeOne committing US$5,000,000 over three years to support patient education, community engagement, and the blood cancer care continuum. Reinforces BeOne's hematology narrative and patient-centric approach.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Glenmark signed billion-dollar licensing deals with BeiGene to commercialize lung cancer and other oncology drugs across emerging markets. Treatments offered at ₹50,000 per session compared to ₹200,000-500,000 for Western alternatives, significantly expanding patient access.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Strategic licensing collaboration for CDK2 inhibitor development targeting RAS-mutated tumors, part of BeOne's shift toward personalized and precision medicine approaches in prostate cancer and other solid tumors.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership on zanidatamab (Ziihera) for HER2-positive cancers. Positive Phase 3 data in gastroesophageal adenocarcinoma showed significant improvements in PFS and OS. Ziihera approved for biliary tract cancer with PDUFA date August 25, 2026 for GEA.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Jazz Pharmaceuticals collaborating on commercialization of zanidatamab in HER2-positive gastroesophageal adenocarcinoma. Expects FDA approval and market launch in second half of 2026 with up to $1.5 billion in potential milestone payments from collaboration.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment9 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BeiGene

Oncology Pharmaceuticalsbeigene.com

BeOne Medicines (formerly BeiGene) is a global oncology company developing and commercializing BRUKINSA, TEVIMBRA, and BEQALZI across 80+ markets, with proprietary protein degradation (CDAC) and ADC platforms and a deep hematology and solid tumor pipeline.

What BeiGene does

BeOne Medicines I GmbH, operating as BeOne Medicines and formerly known as BeiGene, is a global oncology company founded in 2010 and headquartered in Basel, Switzerland (with major operations in Beijing and San Mateo). The company is dual-listed on NASDAQ (ticker ONC), HKEX, and the Shanghai Stock Exchange and markets three approved cancer medicines: BRUKINSA (zanubrutinib), the leading global BTK inhibitor approved in more than 80 markets and generating $3.9 billion in FY2025 sales at 49% year-over-year growth; TEVIMBRA (tislelizumab), a PD-1 inhibitor approved in multiple solid tumor indications; and BEQALZI (sonrotoclax), the first and only FDA-approved BCL2 inhibitor for B-cell malignancies, approved in May 2026.

The company's pipeline spans hematology and solid tumors and includes BTK degraders (BGB-16673/tacabrutideg), a CDK4 inhibitor entering Phase 3 for first-line metastatic breast cancer, the anti-TIGIT antibody ociperlimab, the HPK1 inhibitor BGB-26808, the PRMT5 inhibitor BGB-58067, and the GPC3×4-1BB bispecific BGB-B2033. Underlying these programs are two proprietary technology platforms: CDAC (Conditionally Active Biodegradable Antibody Conjugates), a protein degradation modality, and an enhanced Antibody Drug Conjugate (ADC) platform. Clinical differentiation is anchored by long-duration efficacy data, including 71.8% progression-free survival at 78-month follow-up in CLL/SLL (SEQUOIA trial) and an 85.1% overall response rate for the BTK degrader in heavily pretreated relapsed/refractory CLL.

BeOne Medicines operates a hybrid commercial model: direct sales infrastructure across more than 80 markets including the US, EU, and China, supplemented by licensing partnerships such as the Glenmark deal for emerging markets and the Jazz Pharmaceuticals collaboration on zanidatamab (Ziihera). FY2025 product revenue reached $5.3 billion (40% year-over-year growth) at 88% gross margin, generating the company's first full-year GAAP net profit of $287 million and more than $940 million in free cash flow. Amgen holds an approximately 20.5% equity stake acquired in 2020.

BeiGene firmographics

Firmographics
Name
BeiGene
Legal name
BeOne Medicines I GmbH
Website
https://beigene.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
BeOne Medicines (formerly BeiGene) is a global oncology company developing and commercializing BRUKINSA, TEVIMBRA, and BEQALZI across 80+ markets, with proprietary protein degradation (CDAC) and ADC platforms and a deep hematology and solid tumor pipeline.
Ownership category
akta.pro rank

BeiGene industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Oncology pharmaceuticals
  • Cancer immunotherapy
  • BTK inhibitors
  • PD-1 inhibitors
  • Hematology treatments

Where BeiGene is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices3 records

Markets served

BeiGene business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Product Revenue - BRUKINSA: BRUKINSA (zanubrutinib) is the company's flagship BTK inhibitor generating $3.9 billion in global sales in FY2025, representing 49% year-over-year growth. The drug is approved in 80 markets and maintains position as the leading BTK inhibitor globally. BRUKINSA generated $1.1 billion in Q4 2025 and is on track to generate approximately $5 billion in revenue in 2026.
  2. Product Revenue - Tevimbra: Tevimbra (tislelizumab) is the company's PD-1 inhibitor generating $206 million in Q1 2026 revenue, 7% above analyst estimates. The drug is approved in multiple indications and received priority review from US FDA for first-line HER2+ gastroesophageal adenocarcinoma.
  3. Product Revenue - BEQALZI (sonrotoclax): BEQALZI (sonrotoclax) received FDA approval in May 2026 as the first and only BCL2 inhibitor for certain B-cell malignancies, representing a new revenue stream for the company. The drug has also received Breakthrough Therapy Designation for relapsed or refractory mantle cell lymphoma.
  4. Partnership Revenue - Zanidatamab/Ziihera: BeOne Medicines partnered with Zymeworks on zanidatamab (Ziihera), which received FDA approval for biliary tract cancer and is being developed for HER2-positive gastroesophageal adenocarcinoma. The partnership includes milestone payments and royalty streams, with Jazz Pharmaceuticals collaborating on commercialization.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

BeiGene product offering

Product offering

Core offering

BeOne Medicines is a global oncology company that discovers, develops, manufactures, and commercializes proprietary cancer therapeutics. Its portfolio spans approved drugs (BRUKINSA BTK inhibitor, TEVIMBRA PD-1 inhibitor, BEQALZI BCL2 inhibitor) for hematologic malignancies and solid tumors, plus a deep pipeline of investigational BTK degraders, bispecific antibodies, CDK4/PRMT5/HPK1 inhibitors and TIGIT antibodies. The company operates direct commercial infrastructure across 80+ markets and licenses products in emerging geographies to broaden patient access.

Product overview

BeOne Medicines (BeiGene) is a global oncology company developing a broad portfolio of cancer medicines. The company's approved products include BRUKINSA (zanubrutinib), a leading BTK inhibitor approved in over 80 markets for B-cell malignancies; TEVIMBRA (tislelizumab), a PD-1 inhibitor for various solid tumors; and BEQALZI (sonrotoclax), a BCL2 inhibitor approved in May 2026. The pipeline includes investigational BTK degraders (BGB-16673, tacabrutideg), a PRMT5 inhibitor (BGB-58067), a bispecific antibody (BGB-B2033), a TIGIT inhibitor (ociperlimab), an HPK1 inhibitor (BGB-26808), and a CDK4 inhibitor in Phase 3 development. The company also develops proprietary technology platforms including CDAC (protein degradation) and ADC (antibody drug conjugates). Research focuses on hematology (blood cancers) and solid tumors (breast, gynecologic, gastrointestinal, lung, liver cancers).

Differentiator

Problem solved

Functional benefit

Products and services

  • BRUKINSA (zanubrutinib) Bruton's tyrosine kinase (BTK) inhibitor approved for the treatment of B-cell malignancies including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Waldenström's macroglobulinemia, and marginal zone lymphoma. BRUKINSA is the leading BTK inhibitor globally, approved in 80+ markets, and generated $3.9B in FY2025 sales with 49% YoY growth.
  • TEVIMBRA (tislelizumab) Anti-PD-1 monoclonal antibody approved in multiple indications for the treatment of various solid tumors, including lung cancer and HER2-positive gastroesophageal adenocarcinoma. TEVIMBRA generated $206 million in Q1 2026 revenue and has received U.S. FDA Priority Review for first-line HER2+ GEA.
  • BEQALZI (sonrotoclax) Next-generation BCL2 inhibitor approved by the U.S. FDA in May 2026 as the first and only BCL2 inhibitor for certain B-cell malignancies. Demonstrated 100% ORR with 59.5% complete responses in treatment-naive CLL patients and has also received Breakthrough Therapy Designation for relapsed or refractory mantle cell lymphoma.
  • Ziihera (zanidatamab) HER2-targeted bispecific antibody partnered with Zymeworks and co-commercialized with Jazz Pharmaceuticals for HER2-positive cancers. Approved for biliary tract cancer with positive Phase 3 data in gastroesophageal adenocarcinoma; eligible for up to $1.5 billion in potential milestone payments.

Quantifiable outcome

  • 74% progression-free survival at 6 years in treatment-naïve CLL patients with BRUKINSA
  • +5 more outcomes

Companies that use BeiGene

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

BeiGene technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

BeiGene partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Blood Cancer UnitedcoreStrategic or Co-development Partner · 1 June 2026Expanded multi-year partnership announced June 2026 with BeOne committing US$5,000,000 over three years to support patient education, community engagement, and the blood cancer care continuum. Reinforces BeOne's hematology narrative and patient-centric approach.
  • GlenmarkcoreChannel Partner/ Reseller/ DistributorGlenmark signed billion-dollar licensing deals with BeiGene to commercialize lung cancer and other oncology drugs across emerging markets. Treatments offered at ₹50,000 per session compared to ₹200,000-500,000 for Western alternatives, significantly expanding patient access.
  • Ensem TherapeuticsminorStrategic or Co-development PartnerStrategic licensing collaboration for CDK2 inhibitor development targeting RAS-mutated tumors, part of BeOne's shift toward personalized and precision medicine approaches in prostate cancer and other solid tumors.
  • ZymeworkscoreStrategic or Co-development PartnerPartnership on zanidatamab (Ziihera) for HER2-positive cancers. Positive Phase 3 data in gastroesophageal adenocarcinoma showed significant improvements in PFS and OS. Ziihera approved for biliary tract cancer with PDUFA date August 25, 2026 for GEA.
  • Jazz PharmaceuticalscoreGTM or Marketing PartnerJazz Pharmaceuticals collaborating on commercialization of zanidatamab in HER2-positive gastroesophageal adenocarcinoma. Expects FDA approval and market launch in second half of 2026 with up to $1.5 billion in potential milestone payments from collaboration.

Scale indicators12 records

Recent moves6 records

Expansion highlights7 records

BeiGene competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

BeiGene social profiles

Digital presence

BeiGene financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BeiGene leadership team

Management profile

Number of profiles

Profiles10 records

BeiGene funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BeiGene M&A and investment

M&A and investment

M&A

Investments9 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BeiGene

What does BeiGene do?

BeOne Medicines is a global oncology company that discovers, develops, manufactures, and commercializes proprietary cancer therapeutics. Its portfolio spans approved drugs (BRUKINSA BTK inhibitor, TEVIMBRA PD-1 inhibitor, BEQALZI BCL2 inhibitor) for hematologic malignancies and solid tumors, plus a deep pipeline of investigational BTK degraders, bispecific antibodies, CDK4/PRMT5/HPK1 inhibitors and TIGIT antibodies. The company operates direct commercial infrastructure across 80+ markets and licenses products in emerging geographies to broaden patient access.

Is BeiGene a public or private company?

BeiGene is a public company. It is classified as public and is currently operating.

When was BeiGene founded?

BeiGene was founded in 2010. It employs 1,001 to 5,000 people.

Where is BeiGene based?

BeiGene is headquartered in Cambridge, United States, in the North America region.

How does BeiGene make money?

Four revenue lines are on record. Product Revenue - BRUKINSA is the primary driver. The others are product Revenue - Tevimbra, product Revenue - BEQALZI (sonrotoclax) and partnership Revenue - Zanidatamab/Ziihera.

Does BeiGene have an API?

No public API is recorded for BeiGene.

What industry is BeiGene in?

BeiGene's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MoomooBravera Bio Secures $171 Million in Series A Funding to Focus on Novel Oncology DrugsBravera Bio closed a $171.09 million Series A round co-led by venBio and others, with BeiGene's subsidiary investing $19.5 million. The deal gives BeiGene about 9.477% equity, and the company will receive funds in three tranches contingent on milestones.STATBeOne, Hengrui top list of China’s most powerful drugmakersSTAT and WireScreen published China's Biotech Powerhouse 25, ranking BeOne Medicines and Jiangsu Hengrui Pharmaceuticals as the top two firms, each worth nearly $50 billion. The rankings use market value and revenue, and the list updates quarterly. U.S. policy responses remain uncertain amid geopolitical tensions.Jiemian百济神州:拟1950万美元参与Bravera A轮融资BeiGene Switzerland will invest $19.5 million in BraveraBio's Series A financing, converting $500,000 SAFE into preferred shares. The deal gives BeiGene Switzerland a 9.477% stake, and it is a related-party transaction that does not require board or shareholder approval.MoomooHong Kong Stock Market Movers | BeiGene (06160) Rises Over 3% in Early Trading; Full-Year Revenue Guidance Raised for the Third Time This Year as Innovation Pipeline Approaches Commercialization PhaseBeiGene shares rose over 3% in early trading, up 2.86% to HK$259. The company raised its 2026 full-year revenue forecast a third time this year, from RMB 44.9-46.2 billion to RMB 46.3-47.0 billion, after Q3 revenue of RMB 34.993 billion. Analysts cite pipeline progress and new indications as growth drivers.MoomooThe total market value of BeiGene's (06160) deposited shares stands at HK$32.786 billion, as shareholders deposited 130 million shares with Citi.On November 11, BeiGene's deposited shares were valued at HK$32.786 billion, representing 8.43% of the portfolio. A shareholder deposited 130 million shares with Citi, raising their holding ratio by 8.46%. Lion Securities raised its target price to HK$336.8 and revised revenue forecasts up by 3.9% for 2026–2028.JiemianBaijia Shenzhou has once again raised its performance expectations, with Baiyueze supporting over 70% of its revenue.BeiGene reported Q3 2026 revenue of 12.774 billion yuan and net profit of 2.785 billion yuan, a year-on-year increase of 304.3%. The company's excessive reliance on a single product has become increasingly prominent, with Baiyueze supporting over 70% of its revenue.MoomooHong Kong Stock Market Open | Hang Seng Index Opens 0.70% Higher; BeiGene (06160) Surges 7.57%; Pharmaceutical Stocks StrengthenOn November 10, the Hang Seng Index opened 0.70% higher at 24,621.13 points, with BeiGene leading gains at 7.57%. BeiGene reported Q3 revenue of RMB 34.993 billion, up 26.81% year-on-year, and net profit up 431.81%. Pharmaceutical and tech stocks strengthened, while energy and property stocks declined.MoomooHK Stock Market Watch | BeiGene (06160) opens more than 7% higher; adjusted net profit for the first three quarters rises 96% year-on-year. Citi notes that Brukinsa continues to outperform expectations.BeiGene opened 7.57% higher at HK$267, with Q3 2026 revenue of $1.89B, up 34% year-over-year, and adjusted net profit of $539M, up 77%. Citi raised fiscal 2026 revenue guidance to $6.9B-$7.0B, citing Brukinsa's outperformance.MoomooBeiGene (688235.SH) released its performance results for the first three quarters, reporting net profit attributable to shareholders of RMB 6.055 billion, a year-on-year increase of 431.8%.BeiGene reported its third-quarter 2026 results, with operating revenue of RMB 34.993 billion, up 26.8% year on year. Net profit attributable to shareholders was RMB 6.055 billion, up 431.8%, and basic earnings per share were RMB 4.16. Growth was driven by increased product revenue and improved operational efficiency.Defense WorldBeOne Medicines (NASDAQ:ONC) Price Target Raised to $435.00Wells Fargo raised its price target on BeOne Medicines to $435 from $400, keeping an overweight rating. The stock opened at $406.96, with an average analyst target of $434.79 and a Moderate Buy rating. Insiders sold 261,362 shares in the last quarter.